Abstract: The results show that the investigated laser treatment is effective in reducing subretinal fluid and leads to an improvement of functional parameters.
Introduction
Central serous chorioretinopathy (CSC) is characterized by the accumulation of subretinal fluid (SRF) under the retina, which can lead to visual distortion and a "blister-like" elevation of the macula. While acute cases often resolve spontaneously, the chronic form (cCSC) poses a significant risk of permanent vision loss due to retinal thinning or scarring.
Treating cCSC is challenging. Traditional "thermal" laser photocoagulation effectively stops leaks but causes irreversible tissue damage and macular scarring. Photodynamic therapy (PDT), the current gold standard, is limited by drug shortages and potential side effects. This study evaluates a "subthreshold" laser approach designed to stimulate the eye's natural healing processes without thermal destruction.
Methods
The researchers conducted a prospective, non-randomized interventional study using the Topcon Endpoint Management (EpM) system with a 577 nm yellow laser (PASCAL® Synthesis™). Unlike traditional lasers, EpM uses a continuous wave guided by a mathematical model (the Arrhenius equation) to deliver energy levels that trigger cellular responses—specifically heat shock proteins (HSP)—without reaching the threshold for cell death.
To account for individual pigmentation, the laser was titrated to a "barely visible" level outside the macula (100% energy), with treatment delivered at only 30% of that energy. A standardized circular grid of 400 spots (3000 µm radius) was applied, specifically sparing the fovea to protect central vision.
Study Population and Baseline Data
The study included 42 eyes from 39 patients, many of whom were highly treatment-resistant. Baseline data indicated that 78.6% had failed prior oral mineralocorticoid receptor (MR) antagonists, and 14.3% had failed prior PDT.
Key Results
- Fluid Resolution: Complete resolution of SRF was achieved in 42.9% of eyes at 6 months and 53.8% at 12 months.
- Visual and Functional Improvement: Mean Best Corrected Visual Acuity (BCVA) improved by 4.9 ETDRS letters. Retinal sensitivity, measured via microperimetry, increased from 19.1 dB to 21.3 dB, suggesting an improvement in the quality of vision.
- Anatomical Changes: Central retinal thickness decreased from a mean of 398 µm to 291 µm.
- Predictive Markers: The authors identified a "15% rule": a >15% decrease in retinal thickness by month 3 was a strong predictor of success, with an 80% chance of full resolution by one year.
Discussion and Conclusion
The standardized subthreshold laser therapy effectively reduces subretinal fluid and improves visual function in cCSC patients without causing retinal pigment epithelium (RPE) damage. While the success rate (54%) is slightly lower than half-dose PDT (~67%), its safety profile and ease of use make it a viable alternative, especially for PDT-resistant cases or when PDT is unavailable. The primary limitation remains the lack of a randomized control group, which future studies should address to confirm these findings against the natural history of the disease.
Summary updated